Efforts to reduce healthcare costs often emphasize the air max 270 femme demand side of the economic equation, focusing on areas such as tort reform and consumer-directed healthcare as ways to wring greater efficiencies from the marketplace. But according to Lawton Robert Burns, a professor of healthcare systems at Wharton, we’re not paying enough attention to the supply side, or the cost of developing new medicines and medical devices.
This is the premise of a new book of which Burns is the editor, The Business of Healthcare Innovation. In a review of the book on the school’s Knowledge@Wharton Web site, Burns contends that healthcare technology companies developing devices or drugs should better understand the inner workings of each other. That’s because, “there is a slow but growing convergence of these products. One sector will increasingly rely on another sector for new product development,” he says. As a prime example of this convergence, the article points to drug-coated stents, perhaps the best known device-drug combo. So could Burns is on to something? Maybe. Think back to the late ’70s when chronic, high inflation was hobbling the global economy. The antidote, as it turned out, was so-called supply-side economics, which focused on helping companies create products faster, cheaper and better.http://www.yeezyboostadidas.fr